GenSight Biologics Company

We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. In the longer term, we hope to find solutions for patients faced with neurodegenerative diseases more generally.
Technology: Neurological Disorders
Industry: Energetic Process
Headquarters: France
Founded Date: 2012
Funding Status: IPO
Estimated Revenue: $1M to $10M

Visit Website
Register and Claim Ownership